{"id":77767,"date":"2026-09-02T14:55:10","date_gmt":"2026-09-02T06:55:10","guid":{"rendered":"https:\/\/flcube.com\/?p=77767"},"modified":"2026-09-02T14:55:11","modified_gmt":"2026-09-02T06:55:11","slug":"simcere-zaiming-licenses-sim0660-trispecific-antibody-to-roche-in-up-to-usd-1-53-billion-oncology-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=77767","title":{"rendered":"Simcere Zaiming Licenses SIM0660 Trispecific Antibody to Roche in Up to USD 1.53 Billion Oncology Deal"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Simcere Zaiming Pharmaceutical<\/strong>, an oncology-focused innovative drug company under <strong>Simcere Pharmaceutical<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/2096:HKG\">HKG: 2096<\/a>), announced that it has entered into an exclusive license agreement with <strong>Roche<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/ROP:SWX\">SWX: ROP<\/a>; <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/RHHBY:OTCMKTS\">OTCMKTS: RHHBY<\/a>) to collaborate on the global development and commercialization of <strong>SIM0660<\/strong>, a <strong>CD79a\/CD19\/CD3 trispecific antibody<\/strong> with therapeutic potential for various B-cell related diseases.<\/p>\n\n\n\n<h2 id=\"h-deal-structure-amp-key-terms\" class=\"wp-block-heading\">Deal Structure &amp; Key Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td>Licensor<\/td><td><strong>Simcere Zaiming<\/strong> (under <strong>Simcere Pharmaceutical<\/strong>, HKG: 2096)<\/td><\/tr><tr><td>Licensee<\/td><td><strong>Roche<\/strong><\/td><\/tr><tr><td>Asset<\/td><td><strong>SIM0660<\/strong> \u2013 CD79a\/CD19\/CD3 trispecific antibody<\/td><\/tr><tr><td>Deal Type<\/td><td>Exclusive global license \u2013 development, manufacturing, commercialization<\/td><\/tr><tr><td>Upfront Payment<\/td><td>USD 75 million<\/td><\/tr><tr><td>Total Potential Value<\/td><td>Up to USD 1.53 billion, upfront included<\/td><\/tr><tr><td>Royalties<\/td><td>Tiered, up to double-digit rates on future net sales<\/td><\/tr><tr><td>Announcement Date<\/td><td>01 Sep 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Under the terms of the agreement, <strong>Roche<\/strong> will obtain exclusive rights to develop, manufacture, and commercialize <strong>SIM0660<\/strong> worldwide. <strong>Simcere Zaiming<\/strong> will be eligible to receive up to USD 1.53 billion in total transaction payments, including a USD 75 million upfront payment, and may also be entitled to tiered royalties of up to double digits based on future net sales.<\/p>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> SIM0660, a trispecific T-cell engager (TCE) antibody<\/li>\n\n\n\n<li><strong>Targets:<\/strong> CD3 (T-cell engaging arm) fused with binding domains targeting two B-cell antigens, CD79a and CD19<\/li>\n\n\n\n<li><strong>Platform:<\/strong> Built on <strong>Simcere Zaiming<\/strong>&#8216;s proprietary T-cell engager (TCE) multispecific antibody technology platform<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Redirects T cells to B cells via dual CD79a\/CD19 engagement to drive targeted cell killing<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Effectively limits cytokine release while inducing potent T-cell mediated cytotoxic effects<\/li>\n\n\n\n<li><strong>Potential Scope:<\/strong> Therapeutic potential across various B-cell related diseases<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Deal scale:<\/strong> Total potential consideration of up to USD 1.53 billion underscores strong global appetite for next-generation T-cell engager assets from Chinese biotech<\/li>\n\n\n\n<li><strong>Strategic validation:<\/strong> An exclusive worldwide partnership with <strong>Roche<\/strong> validates <strong>Simcere Zaiming<\/strong>&#8216;s TCE multispecific antibody platform<\/li>\n\n\n\n<li><strong>Competitive positioning:<\/strong> Dual B-cell targeting of CD79a and CD19 combined with a cytokine-release-limiting profile differentiates <strong>SIM0660<\/strong> in the crowded immuno-oncology landscape<\/li>\n\n\n\n<li><strong>Simcere upside:<\/strong> The USD 75 million upfront plus milestone and royalty payments create a multi-year revenue stream tied to the clinical and commercial progress of <strong>SIM0660<\/strong><\/li>\n\n\n\n<li><strong>Sector signal:<\/strong> The transaction adds momentum to the wave of cross-border oncology licensing deals between Chinese innovative drug companies and global pharmaceutical leaders<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2013 This brief contains forward-looking statements regarding the development, milestones, and commercialization of SIM0660. Actual results may differ materially due to clinical, regulatory, and market risks. This content is for informational purposes only and does not constitute investment advice.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simcere Zaiming Pharmaceutical, an oncology-focused innovative drug company under Simcere Pharmaceutical (HKG: 2096), announced that&#8230;<\/p>\n","protected":false},"author":1,"featured_media":78147,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10,4908],"tags":[1099,163,271,1478,939,2790],"class_list":["post-77767","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-pic","tag-hkg-2096","tag-roche","tag-simcere-pharmaceutical","tag-simcere-zaiming-pharmaceutical","tag-swx-rop","tag-t-cell-engager"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Simcere Zaiming Licenses SIM0660 Trispecific Antibody to Roche in Up to USD 1.53 Billion Oncology Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Simcere Zaiming Pharmaceutical, an oncology-focused innovative drug company under Simcere Pharmaceutical (HKG: 2096), announced that it has entered into an exclusive license agreement with Roche (SWX: ROP; OTCMKTS: RHHBY) to collaborate on the global development and commercialization of SIM0660, a CD79a\/CD19\/CD3 trispecific antibody with therapeutic potential for various B-cell related diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=77767\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Simcere Zaiming Licenses SIM0660 Trispecific Antibody to Roche in Up to USD 1.53 Billion Oncology Deal\" \/>\n<meta property=\"og:description\" content=\"Simcere Zaiming Pharmaceutical, an oncology-focused innovative drug company under Simcere Pharmaceutical (HKG: 2096), announced that it has entered into an exclusive license agreement with Roche (SWX: ROP; OTCMKTS: RHHBY) to collaborate on the global development and commercialization of SIM0660, a CD79a\/CD19\/CD3 trispecific antibody with therapeutic potential for various B-cell related diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=77767\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-02T06:55:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-02T06:55:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0201.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77767#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77767\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Simcere Zaiming Licenses SIM0660 Trispecific Antibody to Roche in Up to USD 1.53 Billion Oncology Deal\",\"datePublished\":\"2026-09-02T06:55:10+00:00\",\"dateModified\":\"2026-09-02T06:55:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77767\"},\"wordCount\":424,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77767#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/0201.webp\",\"keywords\":[\"HKG: 2096\",\"Roche\",\"Simcere Pharmaceutical\",\"Simcere Zaiming Pharmaceutical\",\"SWX: ROP\",\"T cell engager\"],\"articleSection\":[\"Company\",\"Deals\",\"PIC\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77767#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77767\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=77767\",\"name\":\"Simcere Zaiming Licenses SIM0660 Trispecific Antibody to Roche in Up to USD 1.53 Billion Oncology Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77767#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77767#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/0201.webp\",\"datePublished\":\"2026-09-02T06:55:10+00:00\",\"dateModified\":\"2026-09-02T06:55:11+00:00\",\"description\":\"Simcere Zaiming Pharmaceutical, an oncology-focused innovative drug company under Simcere Pharmaceutical (HKG: 2096), announced that it has entered into an exclusive license agreement with Roche (SWX: ROP; OTCMKTS: RHHBY) to collaborate on the global development and commercialization of SIM0660, a CD79a\\\/CD19\\\/CD3 trispecific antibody with therapeutic potential for various B-cell related diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77767#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77767\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77767#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/0201.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/0201.webp\",\"width\":1080,\"height\":608,\"caption\":\"Simcere Zaiming Licenses SIM0660 Trispecific Antibody to Roche in Up to USD 1.53 Billion Oncology Deal\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77767#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Simcere Zaiming Licenses SIM0660 Trispecific Antibody to Roche in Up to USD 1.53 Billion Oncology Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Simcere Zaiming Licenses SIM0660 Trispecific Antibody to Roche in Up to USD 1.53 Billion Oncology Deal - Insight, China&#039;s Pharmaceutical Industry","description":"Simcere Zaiming Pharmaceutical, an oncology-focused innovative drug company under Simcere Pharmaceutical (HKG: 2096), announced that it has entered into an exclusive license agreement with Roche (SWX: ROP; OTCMKTS: RHHBY) to collaborate on the global development and commercialization of SIM0660, a CD79a\/CD19\/CD3 trispecific antibody with therapeutic potential for various B-cell related diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=77767","og_locale":"en_US","og_type":"article","og_title":"Simcere Zaiming Licenses SIM0660 Trispecific Antibody to Roche in Up to USD 1.53 Billion Oncology Deal","og_description":"Simcere Zaiming Pharmaceutical, an oncology-focused innovative drug company under Simcere Pharmaceutical (HKG: 2096), announced that it has entered into an exclusive license agreement with Roche (SWX: ROP; OTCMKTS: RHHBY) to collaborate on the global development and commercialization of SIM0660, a CD79a\/CD19\/CD3 trispecific antibody with therapeutic potential for various B-cell related diseases.","og_url":"https:\/\/flcube.com\/?p=77767","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-09-02T06:55:10+00:00","article_modified_time":"2026-09-02T06:55:11+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0201.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=77767#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=77767"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Simcere Zaiming Licenses SIM0660 Trispecific Antibody to Roche in Up to USD 1.53 Billion Oncology Deal","datePublished":"2026-09-02T06:55:10+00:00","dateModified":"2026-09-02T06:55:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=77767"},"wordCount":424,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=77767#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0201.webp","keywords":["HKG: 2096","Roche","Simcere Pharmaceutical","Simcere Zaiming Pharmaceutical","SWX: ROP","T cell engager"],"articleSection":["Company","Deals","PIC"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=77767#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=77767","url":"https:\/\/flcube.com\/?p=77767","name":"Simcere Zaiming Licenses SIM0660 Trispecific Antibody to Roche in Up to USD 1.53 Billion Oncology Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=77767#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=77767#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0201.webp","datePublished":"2026-09-02T06:55:10+00:00","dateModified":"2026-09-02T06:55:11+00:00","description":"Simcere Zaiming Pharmaceutical, an oncology-focused innovative drug company under Simcere Pharmaceutical (HKG: 2096), announced that it has entered into an exclusive license agreement with Roche (SWX: ROP; OTCMKTS: RHHBY) to collaborate on the global development and commercialization of SIM0660, a CD79a\/CD19\/CD3 trispecific antibody with therapeutic potential for various B-cell related diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=77767#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=77767"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=77767#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0201.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0201.webp","width":1080,"height":608,"caption":"Simcere Zaiming Licenses SIM0660 Trispecific Antibody to Roche in Up to USD 1.53 Billion Oncology Deal"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=77767#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Simcere Zaiming Licenses SIM0660 Trispecific Antibody to Roche in Up to USD 1.53 Billion Oncology Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0201.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77767","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=77767"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77767\/revisions"}],"predecessor-version":[{"id":78146,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77767\/revisions\/78146"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/78147"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=77767"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=77767"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=77767"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}